Match each pharmacological agent used in psychiatric practice with its characteristic adverse effect profile or specific clinical warning regarding its use in bipolar disorder.
- LithiumRequires baseline and periodic monitoring of serum creatinine and thyroid-stimulating hormone (TSH).
- ValproateAssociated with dose-related thrombocytopenia, hepatotoxicity, and significant teratogenic risks (neural tube defects).
- QuetiapineAn atypical antipsychotic associated with significant weight gain, dyslipidemia, and insulin resistance; requires regular metabolic monitoring.
- SertralineAn antidepressant that carries a high risk of precipitating a manic switch if used as monotherapy in patients with bipolar depression.
Cevap
Lithium pairs with renal/thyroid monitoring; Valproate pairs with hepatotoxicity and neural tube defects; Quetiapine pairs with metabolic syndrome monitoring; Sertraline pairs with the risk of precipitating a manic switch.
Each medication plays a specific role in psychiatric care and has a uniquely identifiable risk profile. Lithium affects the kidneys and thyroid. Valproate affects the liver and platelets, and is teratogenic. Quetiapine causes metabolic derangements. Sertraline, while an effective antidepressant, can dangerously precipitate mania in bipolar patients.
Adım Adım Çözüm
Anahtar Kavram
Pharmacological management of bipolar disorder: adverse effects, monitoring guidelines, and contraindications.